ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RGNX vs EDIT // FREE CASH FLOW YIELD

REGENXBIO Inc. (NASDAQ) VS. Editas Medicine Inc. (NASDAQ) • 15-METRIC TALLY: RGNX 3 — EDIT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGNX VS. EDIT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RGNX EDIT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 104.50% 25.40% +79.10 RGNX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 RGNX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.4 50.8 -4.38 EDIT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $489.2M $450.0M $39.2M RGNX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RGNX REV EDIT REV RGNX GROSS % EDIT GROSS % RGNX FCF EDIT FCF
FY 2025 $170.4M $40.5M — — -$126.4M -$165.8M
FY 2024 $83.3M $32.3M 59.7% — -$175.6M -$219.1M
FY 2023 $90.2M $78.1M — — -$218.4M -$132.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGNX // BETA —
EDIT // BETA —